The States approved proposals in January 2021 and HSC undertook a 2-year process to implement a NICE TA programme. 

HSC is currently reviewing the implementation process with a mind to propose future funding for the medicines and treatments within the NICE TA programme. 

Carewatch said: “Evidence from the Review suggested that over 3000 bailiwick patients could expect to receive hundreds of new drugs or treatments, extending life, reducing often uncomfortable side effects, helping to maintain a greater quality of life during treatment than some existing treatment pathways, over a wide range of serious health conditions including cancer, heart conditions, diabetes, MS and many more.” 

The review is a two-parter, with an independent organisation called Solutions for Public Health undertaking an in-depth clinical and financial analysis.

The local panel Carewatch will be undertaking the second part of that review, seeking feedback from people in the community who’ve been prescribed NICE TAs. The panel is comprised of various members of the community, including representatives from the voluntary sector. 

The panel said: “When the Committee recommended the introduction of NICE TAs, it did so on the basis that, among other things, the treatments would likely improve patient outcomes and experience by reducing uncomfortable or painful side effects and adverse events.  

“CareWatch are keen to hear if these benefits, or others, have been realised. Similarly, it would gladly receive any negative observations and from any groups involved in patient representation.” 

Responses are required before the 14 July and you can find the details on how to get involved with the review below: